Samsung Biologics Enters CRO Market to Enhance Clinical Trials
Seoul, Friday, 20 June 2025.
Samsung Biologics, the world’s largest CDMO, will expand into the CRO market, leveraging its vast drug production capacity and expertise to enhance clinical trial processes and efficiency.
Strategic Expansion into the CRO Market
On 16 June 2025, Samsung Biologics announced its strategic expansion into the contract research organization (CRO) market. This move leverages its status as the world’s largest contract development and manufacturing organization (CDMO), underlined by its robust drug production capacity of 784,000 liters, which is set to expand to 964,000 liters by 2027 [3].
Enhancing Clinical Trial Capabilities
Samsung Biologics aims to offer comprehensive CRO services that will include critical elements of the clinical trial process such as clinical trial design, patient recruitment, data collection, regulatory compliance, and results reporting [3]. The company seeks to establish a ‘lock-in effect’ with its clients by engaging them from the initial stages of drug discovery, supported by its advanced drug production capabilities [3].
Global Impact and Industry Position
Strategically positioning itself within the rapidly growing CRO market, Samsung Biologics plans to capitalize on South Korea’s robust clinical trial infrastructure. South Korea ranked sixth globally in clinical trial activity in 2024 with a 3.46% share, showcasing its pivotal role in the global pharmaceutical research landscape [3].
Innovative Approaches in Drug Development
Samsung Biologics is also innovating within the industry by leveraging organoid technology in drug discovery and testing. With the FDA’s plans to phase out animal testing for monoclonal antibodies, Samsung Biologics is poised to reduce research and development costs while accelerating drug testing and approval timelines [3].